临床特征

总人数

生存状态

统计值

P值

生存

死亡

性别[例(%)]

χ² = 3.501

P = 0.061

男性

264 (61.5)

96 (56.1)

168 (65.1)

女性

165 (38.5)

75 (43.9)

90 (34.9)

年龄[例(%)]

χ² = 9.027

P = 0.003

≥60岁

275 (64.1)

95 (55.6)

180 (69.8)

<60岁

154 (35.9)

76 (44.4)

78 (30.2)

TNM分期[例(%)]

χ² = 73.485

P < 0.001

I期~IIIA期

156 (36.4)

104 (60.8)

52 (20.2)

IIIB期~IVB期

273 (63.6)

67 (39.2)

206 (79.8)

病理分型[例(%)]

χ² = 1.700

P = 0.192

腺癌

335 (78.1)

139 (81.3)

196 (76.0)

鳞癌

94 (21.9)

32 (18.7)

62 (24.0)

手术治疗[例(%)]

χ² = 30.370

P < 0.001

有

149 (34.7)

86 (50.3)

63 (24.4)

无

280 (65.3)

85 (49.7)

195 (75.6)

吸烟史[例(%)]

χ² = 3.372

P = 0.066

有

209 (48.7)

74 (43.3)

135 (52.3)

无

220 (51.3)

97 (56.7)

123 (47.7)

前白蛋白(mg/L, $\overline{x}$ ± s)

242.09 ± 63.59

262.12 ± 64.92

228.82 ± 59.17

t = 5.49

P < 0.001

癌胚抗原 [ng/mL, M(Q₁, Q₃)]

4.94

(2.27, 19.46)

3.04

(1.90, 8.60)

8.03

(2.85, 27.7)

Z = −5.525

P < 0.001

可溶性细胞角蛋白19片段[ng/mL, M(Q₁, Q₃)]

3.83

(2.55, 7.53)

3.12

(2.17, 4.84)

4.54

(3.00, 9.78)

Z = −5.619

P < 0.001

神经元特异性烯醇化酶[ng/mL, M(Q₁, Q₃)]

15.65

(12.62, 19.87)

14.3

(12.2, 17.7)

16.4

(13.0, 21.5)

Z = −3.625

P < 0.001

D-二聚体 [mg/mL, M(Q₁, Q₃)]

0.52

(0.32, 1.09)

0.390

(0.265, 0.670)

0.660

(0.383, 1.33)

Z = −5.740

P < 0.001

SII [M(Q₁, Q₃)]

652.47

(395.06, 1016.64)

472

(315, 849)

781

(489, 1132)

Z = −5.734

P < 0.001

SII/ALB [M(Q₁, Q₃)]

16.99

(9.83, 29.11)

11.9

(7.86, 21.4)

21.2

(12.2, 31.3)

Z = −5.987

P < 0.001

CAR [M(Q₁, Q₃)]

0.14

(0.03, 0.44)

0.0697

(0.0150, 0.238)

0.275

(0.0631, 0.518)

Z = −5.941

P < 0.001

PLR [M(Q₁, Q₃)]

155.26

(115.40, 206.13)

135

(109, 176)

163

(122, 222)

Z = −4.009

P < 0.001